In the BioHarmony Drug Report Database

"Preview" Icon

Oxymetazoline

Ocuclear, Rhofade, Upneeq, Visine L.r (oxymetazoline) is a small molecule pharmaceutical. Oxymetazoline was first approved as Ocuclear on 1986-05-30. It is used to treat common cold, conjunctivitis, rhinitis, and sinusitis in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor and alpha-2A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1B, alpha-2C adrenergic receptor, and 5-hydroxytryptamine receptor 1D. Afrin original’s patents are valid until 2039-12-16 (FDA).

 

Trade Name

 

Ocuclear, Rhofade, Upneeq, Visine L.r
 

Common Name

 

oxymetazoline
 

ChEMBL ID

 

CHEMBL762
 

Indication

 

common cold, conjunctivitis, rhinitis, sinusitis
 

Drug Class

 

Antihistamines/local vasoconstrictors (antazoline type)

Image (chem structure or protein)

Oxymetazoline structure rendering